Biovail
Biovail and Athpharma terminate joint development agreement
Published in Cardiovascular Business Week, August 22nd, 2006
As part of this arrangement, Biovail will transfer these four products to Athpharma.
Biovail will retain an ongoing economic interest through a royalty on Athpharma's future net revenues from the products, if and when they are commercialized. Athpharma will also make a cash payment to Biovail as a result of the termination of the agreement. Additionally, Biovail has acquired the option to license certain intellectual property from Athpharma, which would provide future...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Biosite
Biosite notes 45% increase in sales of cardiovascular products - Cytokinetics
Cytokinetics reports $1.4 million in revenue from R & D collaborations in second quarter - Edwards Lifesciences
Edwards Lifesciences reports strong second quarter earnings - Endologix
Endologix reports continued significant growth during second quarter in U.S. product sales - Finance
Merit Medical reports record Q2 2006 revenues of $48.1 million, up 13.5% over Q2 2005 - Millennium Pharmaceuticals
Millennium Pharmaceuticals reports strong Q2 2006 results, progress in marketing Velcade - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
